Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
House Dust Mite, Dermatophagoides Farinae
Brand Name
House Dust Mite, Dermatophagoides Farinae
Generic Name
House Dust Mite, Dermatophagoides Farinae
Active Ingredient
Dermatophagoides FarinaeCategory
Standardized Insect Allergenic Extract [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 10000 [AU]/mL | INJECTION | CUTANEOUS, INTRADERMAL, SUBCUTANEOUS | 49643-702 |
Detailed information about House Dust Mite, Dermatophagoides Farinae
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for House Dust Mite, Dermatophagoides Farinae, you must consult a qualified healthcare professional.
Dermatophagoides Farinae is a standardized allergenic extract used for the diagnosis and treatment of house dust mite-induced allergic rhinitis and conjunctivitis. It belongs to the class of allergen immunotherapies designed to desensitize the immune system through controlled exposure.
For Sublingual Immunotherapy (SLIT), the standard adult dose for Dermatophagoides Farinae (often combined with D. pteronyssinus in products like ODACTRA) is typically one tablet (12 SQ-HDM) taken once daily. There is no 'build-up' phase required for the sublingual tablet form; the maintenance dose is started immediately.
For Subcutaneous Immunotherapy (SCIT), the dosage is highly individualized. It follows a two-phase schedule:
No dosage adjustments are required for patients with renal (kidney) impairment, as the proteins are not cleared by the kidneys in a way that would lead to systemic accumulation.
No dosage adjustments are required for patients with hepatic (liver) impairment.
Clinical trials for SLIT included patients up to age 65. For patients over 65, the efficacy and safety have not been extensively studied. Healthcare providers must assess the patient's overall health, particularly cardiovascular status, as elderly patients may be less able to tolerate the epinephrine required to treat a rare systemic reaction.
An overdose of Dermatophagoides Farinae (taking more than the prescribed amount) significantly increases the risk of severe local and systemic allergic reactions, including anaphylaxis. Signs include swelling of the tongue, throat tightness, difficulty breathing, and a drop in blood pressure. In case of suspected overdose, seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop treatment without medical guidance, as this can affect the efficacy and safety of the immunotherapy.
Because Dermatophagoides Farinae is an allergen, local allergic reactions are expected as the body's immune system interacts with the extract. For Sublingual (SLIT) users, common side effects include:
For Subcutaneous (SCIT) users:
> Warning: Stop taking Dermatophagoides Farinae and call your doctor or emergency services immediately if you experience any of these signs of Anaphylaxis:
There are no known long-term 'toxic' effects of Dermatophagoides Farinae extracts. The primary long-term consideration is the successful modulation of the immune system. However, patients should be monitored for the development of Eosinophilic Esophagitis (EoE) over months or years of sublingual treatment. If a patient develops persistent heart burn or difficulty swallowing, the treatment may need to be permanently discontinued.
Sublingual Dermatophagoides Farinae products (like ODACTRA) carry an FDA Black Box Warning regarding the risk of severe allergic reactions.
Report any unusual symptoms, especially those affecting your breathing or digestion, to your healthcare provider promptly.
Dermatophagoides Farinae extract is a potent biological substance. It is not a symptom-reliever (like an antihistamine) but a disease-modifying therapy. Patients must understand that they are being intentionally exposed to a substance they are allergic to. Safety depends on strict adherence to the prescribed dose and monitoring for systemic symptoms.
Dermatophagoides Farinae generally does not cause drowsiness or impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully evaluated by a medical professional.
There is no direct chemical interaction between alcohol and Dermatophagoides Farinae. However, alcohol consumption can sometimes exacerbate allergic symptoms or mask the early signs of an allergic reaction. It is generally advised to avoid alcohol for a few hours after taking a dose, especially during the build-up phase of SCIT.
If treatment is discontinued for more than a few days, the patient's sensitivity may increase. Do not restart the medication at the previous dose without consulting a physician. Tapering is not usually required for discontinuation, but the 'protective' effect of the immunotherapy will gradually fade if the 3-5 year course is not completed.
> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Dermatophagoides Farinae.
There are no drugs that are strictly 'contraindicated' due to chemical incompatibility; however, certain drugs make the management of side effects dangerously difficult:
For each major interaction, the primary concern is the pharmacodynamic interaction with the emergency treatment (epinephrine) or the additive effect on the immune system's threshold for anaphylaxis.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are on medication for blood pressure, heart rhythm, or depression.
Conditions where Dermatophagoides Farinae must NEVER be used include:
Conditions requiring careful risk-benefit analysis:
Patients allergic to Dermatophagoides Farinae often show cross-reactivity with Dermatophagoides pteronyssinus (the European house dust mite) due to the similarity of their proteins. There is also documented cross-reactivity with other members of the Pyroglyphidae family and occasionally with shellfish (due to the shared protein tropomyosin). Patients with a severe shellfish allergy should be monitored closely, though they are not strictly contraindicated from dust mite therapy.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Dermatophagoides Farinae.
It is not known whether Dermatophagoides Farinae allergens are excreted in human milk. Because these are large proteins that are likely digested in the infant's stomach, the risk to the nursing infant is considered very low. The primary concern is the mother's safety and her ability to manage potential reactions while caring for an infant.
Clinical studies of ODACTRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. The main concern in the elderly is the presence of comorbid conditions (like heart disease) that would make a systemic reaction more dangerous.
No studies have been performed in patients with renal impairment. However, since the allergens are proteins that undergo local proteolysis and are not excreted intact by the kidneys, no dose adjustment is anticipated.
No studies have been performed in patients with hepatic impairment. The liver does not play a primary role in the clearance of these allergenic proteins.
> Important: Special populations, particularly pregnant women and those with underlying respiratory disease, require individualized medical assessment and close supervision by an immunology specialist.
Dermatophagoides Farinae extract works by inducing immunological tolerance. The primary targets are the T-lymphocytes and B-lymphocytes.
| Parameter | Value |
|---|---|
| Bioavailability | Low (systemically); High (locally in oral mucosa) |
| Protein Binding | N/A (Proteins are processed by APCs) |
| Half-life | Minutes to hours (for the proteins themselves) |
| Tmax | Immediate (local contact) |
| Metabolism | Proteolysis by cellular enzymes |
| Excretion | Cellular turnover/metabolic degradation |
Classified as a Standardized Insect Allergenic Extract. It is distinct from non-standardized extracts because its potency is verified against a reference standard, ensuring consistent biological activity across different batches.
Common questions about House Dust Mite, Dermatophagoides Farinae
Dermatophagoides Farinae extract is primarily used for allergen immunotherapy to treat patients with house dust mite-induced allergic rhinitis, which may include symptoms like sneezing, runny nose, and itchy eyes. It is also used by allergists as a diagnostic tool in skin prick testing to confirm if a patient has a specific allergy to North American house dust mites. By exposing the patient to controlled amounts of the allergen, the treatment helps the immune system become less sensitive over time. It is typically reserved for patients whose symptoms are not well-controlled by standard allergy medications or those who wish to reduce their long-term reliance on drugs like antihistamines and nasal steroids.
The most common side effects, particularly with sublingual (under-the-tongue) tablets, include local reactions in the mouth and throat. Patients frequently report itching of the mouth (oral pruritus), a scratchy or irritated throat, and mild swelling of the tongue or lips. These reactions usually occur shortly after taking the dose and typically diminish in frequency and intensity after the first few weeks of treatment. For those receiving injections, redness and swelling at the injection site are the most frequent complaints. While most side effects are mild, it is important to monitor for signs of a systemic reaction, such as hives or difficulty breathing.
There is no known chemical interaction between alcohol and Dermatophagoides Farinae extract; however, caution is advised. Alcohol can cause vasodilation (widening of blood vessels), which might theoretically increase the absorption rate of the allergen and heighten the risk of a systemic reaction. Additionally, being under the influence of alcohol may make it harder for a patient to recognize the early warning signs of anaphylaxis. Most healthcare providers recommend avoiding alcohol for several hours after a dose, especially during the initial phases of treatment when the body is still adjusting to the allergen.
Dermatophagoides Farinae is generally not started during pregnancy due to the risk of anaphylaxis, which could potentially harm the fetus by reducing oxygen supply. However, if a patient is already on a stable maintenance dose and becomes pregnant, many doctors allow the treatment to continue because the risk of a severe reaction is significantly lower at that stage. The decision is always made on a case-by-case basis, weighing the benefits of controlling the mother's allergy and asthma against the potential risks. Pregnant women should always consult their allergist and obstetrician before continuing or starting any immunotherapy.
Immunotherapy is not an immediate fix for allergy symptoms. Most patients begin to notice a reduction in their dust mite allergy symptoms after about 3 to 4 months of consistent daily treatment with sublingual tablets or after reaching the maintenance phase of injections. However, for the most significant and long-lasting results, the treatment must usually be continued for 3 to 5 years. This extended duration allows the immune system to undergo a more permanent 'reprogramming,' providing relief that can persist even after the medication is discontinued.
Yes, you can stop taking Dermatophagoides Farinae suddenly without experiencing withdrawal symptoms like those seen with some other medications. However, stopping the treatment prematurely, especially before the 3-year mark, likely means that your allergy symptoms will eventually return to their original severity. If you miss doses for more than a few days, you should not restart at the same dose without talking to your doctor, as your sensitivity may have increased during the break. Always discuss your plans with your healthcare provider to ensure you don't lose the progress you've made.
If you miss a single daily dose of a sublingual tablet, simply skip the missed dose and take your next scheduled dose the following day. Do not take two doses at once to make up for the one you missed. If you miss more than 7 days of treatment, it is crucial to contact your healthcare provider before resuming, as they may want you to restart at a lower dose to ensure safety. For missed allergy shots (SCIT), you must contact your allergist's office to determine the appropriate adjusted dose for your next visit.
There is no clinical evidence to suggest that Dermatophagoides Farinae allergenic extracts cause weight gain. Unlike systemic corticosteroids, which are sometimes used for severe allergies and are known to affect metabolism and appetite, allergenic extracts are proteins that act locally on the immune system. Any changes in weight while taking this medication are likely due to other factors, such as lifestyle changes or other medications. If you experience unexpected weight changes, you should discuss them with your primary care physician.
Dermatophagoides Farinae can be taken with most common medications, including antihistamines and nasal steroids, which are often used together at the start of treatment. However, it can have dangerous interactions with medications that affect your body's response to emergency treatment. Specifically, beta-blockers (used for heart conditions) and certain antidepressants (MAOIs) can make it difficult to treat a severe allergic reaction if one occurs. Always provide your doctor with a full list of your current medications to ensure that immunotherapy is a safe option for you.
Dermatophagoides Farinae is a biological product rather than a simple chemical drug, so it does not have 'generics' in the traditional sense. Instead, there are various 'branded' standardized extracts produced by different laboratories, such as Greer, HollisterStier, and ALK-Abelló. While these extracts all contain the same house dust mite proteins, they are not always considered bioequivalent or interchangeable. Sublingual tablets like ODACTRA are currently only available as brand-name products. You should always use the specific brand or formulation prescribed by your allergist to ensure consistent dosing.
Other drugs with the same active ingredient (Dermatophagoides Farinae)